Insilico Medicine

Insilico Medicine is a clinical-stage biotechnology company applying generative AI and robotic automation to drug discovery and development. Its Pharma.AI software suite includes PandaOmics (target discovery from multi-omics data), Chemistry42 (generative chemistry with retrosynthesis, property prediction, and ADMET), Generative Biologics, inClinico (clinical trial outcome prediction), Science42 DORA (research assistant), Nach01, and PreciousGPT-family models for life sciences. The company runs its own therapeutic pipeline spanning oncology, fibrosis, and inflammation, with programs targeting TNIK, USP1, QPCTL, PHD, MAT2A, TEAD, ENPP1, KAT6 and others through Phase II. Insilico monetizes through Pharma.AI software licensing, partnerships with major pharmaceutical companies, and progression of its in-house assets. Pharma.AI tools are commercial SaaS products accessed via web UI; the company publishes open-source research code on GitHub (GENTRL, fcd_torch, BiAAE, DD-VAE, DORA) but does not expose a public commercial API.

Insilico Medicine is profiled on the APIs.io network. Tagged areas include Drug Discovery, Biotech, Pharmaceuticals, Generative AI, and Generative Chemistry.

Insilico Medicine’s developer surface includes engineering blog and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

Drug DiscoveryBiotechPharmaceuticalsGenerative AIGenerative ChemistryTarget DiscoveryMulti-OmicsAgingLongevityClinical TrialsADMETRetrosynthesisPharma.AIChemistry42PandaOmics

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 7.9/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/insilico-medicine: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 7

The organization behind the API

Website

Website

InvestorRelations

Newsroom

Blog

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 4

Properties that don't map to a standard resource type

Platform

Pipeline

Products

Publications

Source (apis.yml)

aid: insilico-medicine
name: Insilico Medicine
description: Insilico Medicine is a clinical-stage biotechnology company applying generative AI and robotic automation to
  drug discovery and development. Its Pharma.AI software suite includes PandaOmics (target discovery from multi-omics data),
  Chemistry42 (generative chemistry with retrosynthesis, property prediction, and ADMET), Generative Biologics, inClinico
  (clinical trial outcome prediction), Science42 DORA (research assistant), Nach01, and PreciousGPT-family models for life
  sciences. The company runs its own therapeutic pipeline spanning oncology, fibrosis, and inflammation, with programs targeting
  TNIK, USP1, QPCTL, PHD, MAT2A, TEAD, ENPP1, KAT6 and others through Phase II. Insilico monetizes through Pharma.AI software
  licensing, partnerships with major pharmaceutical companies, and progression of its in-house assets. Pharma.AI tools are
  commercial SaaS products accessed via web UI; the company publishes open-source research code on GitHub (GENTRL, fcd_torch,
  BiAAE, DD-VAE, DORA) but does not expose a public commercial API.
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
position: Provider
access: 3rd-Party
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/insilico-medicine.png
tags:
- Drug Discovery
- Biotech
- Pharmaceuticals
- Generative AI
- Generative Chemistry
- Target Discovery
- Multi-Omics
- Aging
- Longevity
- Clinical Trials
- ADMET
- Retrosynthesis
- Pharma.AI
- Chemistry42
- PandaOmics
url: https://raw.githubusercontent.com/api-evangelist/insilico-medicine/refs/heads/main/apis.yml
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.20'
apis: []
common:
- type: DomainSecurity
  url: security/insilico-medicine-domain-security.yml
- type: Website
  url: https://insilico.com
- type: Platform
  url: https://pharma.ai
- type: Pipeline
  url: https://insilico.com/pipeline
- type: Products
  url: https://insilico.com/platform
- type: Publications
  url: https://insilico.com/publications
- type: InvestorRelations
  url: https://ir.insilico.com
- type: Newsroom
  url: https://insilico.com/news
- type: Blog
  url: https://insilico.com/blog
- type: Careers
  url: https://insilico.com/careers
- type: GitHubOrganization
  url: https://github.com/insilicomedicine
- type: LinkedIn
  url: https://www.linkedin.com/company/insilico-medicine
- type: Twitter
  url: https://twitter.com/InSilicoMeds
- type: Contact
  url: https://insilico.com/contact
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com